The rules around peptides are being rewritten. We track every move.
A clear, no-hype briefing on peptide research, recategorization timelines, and the regulatory decisions shaping what comes next — including the FDA Pharmacy Compounding Advisory Committee review on July 23–24, 2026.
Free briefing + priority waitlist · No hype, no spam · Unsubscribe anytime
A standing briefing on a fast-moving space.
One email, sent when there’s something real to report. Built for people who want to understand the peptide story as it actually unfolds — not the hype around it.
Regulatory timelines, tracked
Key dates, committee meetings, and recategorization milestones — what's happening and when. Starting with the FDA Pharmacy Compounding Advisory Committee review on July 23–24, 2026.
Research, summarized plainly
Plain-English digests of emerging peptide research and what the data and the regulatory process actually show. No spin, no overpromising — just where things stand.
Industry movement
How the 503A and 503B compounding landscape, suppliers, and the broader market are shifting — the signals worth paying attention to as the space matures.
Priority on the waitlist
If and when compliant options open following regulatory clarity, subscribers are first to know — ahead of any public launch.
The timeline that matters.
A lot hinges on a small number of regulatory moments. Here’s the one shaping the near-term outlook — and what subscribers will get as it plays out.
- Right now
An unsettled category
Research and compounding activity continue across peptides while the regulatory picture takes shape. We summarize what's verifiable and skip the rest.
- July 23–24, 2026
FDA Pharmacy Compounding Advisory Committee
The committee is set to review nominated substances — including peptides such as BPC-157 and TB-500 — relevant to the compounding lists. This is the date everyone in the space is watching.
- After the meeting
Reading the outcome
Committee discussion and any recommendations help shape what compliant, compounded options could look like going forward. We'll break down what it actually means — in plain language.
Get the briefing before the next decision lands.
Join the newsletter and the priority waitlist. Free, occasional, and genuinely useful — unsubscribe whenever you like.
News & information only · Not medical advice
News & Information — Not Medical Advice
AetherPeptide is an independent news and information service covering peptide research and regulatory developments. We are not a pharmacy, drug manufacturer, or healthcare provider, and nothing here is medical advice. All content is for general informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Joining the newsletter or waitlist is not a purchase and does not create a patient–provider relationship. “Priority access” refers only to future, compliant options should they become available following regulatory clarity.